|
Status |
Public on May 14, 2023 |
Title |
Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia [scMultiome] |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This study characterized the effect of WEE1 kinase inhibition using AZD1775 treatment on single-cell accessible chromatin and gene expression profile using the 10x Genomics multiome protocol (ATAC + Gene Expression Assay) in the acute lymphoblastic leukemia cell line RS4;11 that represents the KMT2A-rearranged subtype.
|
|
|
Overall design |
scMultiome-seq samples were generated from cells treated for 10 h with AZD1775(Wee1i) or vehicle (DMSO) using the 10x Genomics Chromium platform and protocols generating scRNA-seq and scATAC-seq from the same cells.
|
|
|
Contributor(s) |
Lahnalampi M, Heinäniemi M, Malyukova A, Sangfelt O |
Citation(s) |
38822412 |
|
Submission date |
Dec 05, 2022 |
Last update date |
Jun 26, 2024 |
Contact name |
Merja Heinäniemi |
E-mail(s) |
merja.heinaniemi@uef.fi
|
Organization name |
University of Eastern Finland
|
Department |
School of Medicine, Institute of Biomedicine
|
Lab |
Systems Genomics - Heinäniemi lab
|
Street address |
Yliopistonranta 1E
|
City |
Kuopio |
ZIP/Postal code |
70211 |
Country |
Finland |
|
|
Platforms (1) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
Samples (4)
|
|
This SubSeries is part of SuperSeries: |
GSE220114 |
Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia |
|
Relations |
BioProject |
PRJNA908817 |